PA-RELIEF-THERAPEUTICS
29.7.2020 07:32:11 CEST | Business Wire | Press release
RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTC:RLFTF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that FDA has granted an Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP). The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women. Although the drug remains under investigation, rapid recovery from respiratory failure in COVID-19 has been seen in patients treated under FDA Emergency Use authorization.1
The expanded access protocol may be viewed on www.clinicaltrials.gov NCT04453839. Physicians who wish to enroll their patients in the protocol must submit the protocol to their local investigational review board and file FDA form 1572 with NeuroRx, Inc. Further information may be obtained from expandedaccess@neurorxpharma.com .
“By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment,” said Dr. Jonathan C. Javitt, MD, MPH, NeuroRx’s CEO. “We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program, and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial .”
The SARS-CoV-2 coronavirus that causes COVID-19 attacks the body by entering the small population of Alveolar Type II cells in the lung.2 Without Type II cells, the lung cannot transmit oxygen, which why the coronavirus causes acute respiratory failure. 50 years of scientific research demonstrates that VIP binds specifically to the Type II cell and protects that cell against cytokines (inflammatory molecules) and a wide array of toxic and infectious injuries.”3
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent4 for RLF-100 and proprietary manufacturing processes for its synthesis.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF (ISIN: CH0100191136).
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials.
Disclaimer : This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
1 Youssef JG, Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide doi: 10.20944/preprints202007.0178.v1
2 Mason R. Pathogenesis of COVID-19 from a Cell Biologic Perspective. Eur Respir J. April 9 Epub ahead of print. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144II60/
4 US 8,178,489 Formulation for Aviptadil
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hitachi Energy and Rockwell Automation Unite Power and Automation to Help Industries Accelerate Electrification15.10.2026 13:00:00 CEST | Press release
Grid-to-process approach integrates energy supply and production demand to improve efficiency, optimize resources, and simplify complex industrial projects Brings together deep expertise across domains spanning electrical infrastructure, grid and process automation and digital technologies. Supports a more unified approach to planning, delivering, and operating capital-intensive industrial facilities. Initially focused on mining and metals, with potential applications across other energy-intensive industries. Hitachi Energy, a global leader in electrification, and Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, announced today a collaboration centered on an integrated grid-to-process architecture that combines the infrastructure powering industrial facilities with the systems that manage production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/
ADFD Strengthens Water Security for Serbian Agriculture15.10.2026 12:45:00 CEST | Press release
Nearly US$100 million in concessional financing is supporting irrigation across 122,432 hectares of agricultural land. Abu Dhabi Fund for Development (ADFD) is strengthening water security and agricultural resilience in Serbia through a nearly US$100 million concessional financing programme supporting irrigation infrastructure across five regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015388397/en/ Abu Dhabi Fund For Development's Irrigated Agriculture Development Project in Serbia (Photo: AETOSWire) The development of irrigated agriculture project covers 122,432 hectares of agricultural land, with more than 108,000 hectares already irrigated and a further 14,000 hectares under construction. Infrastructure upgrades include 17 irrigation canals extending over 500 kilometres and more than 60 pumping stations, improving water access, strengthening flood control and supporting more reliable agricultural production. D
Venture Global Secures New Agreements to Support Expansion of Existing Grid-Independent Power Network15.10.2026 12:00:00 CEST | Press release
Landmark Agreement with GE Vernova and Baker Hughes supports the development of over 10 GW of new Island-Mode power capacity across sites owned or controlled by Venture GlobalLeverages existing team and execution capabilities to enable rapid deployment of adjacent, behind-the-wall, large-scale data centers with no reliance on the public electric grid demand or extra cost to consumersStaged, market-driven expansion advances Venture Global’s critical energy infrastructure strategy in a disciplined manner and positions the Company to facilitate power and compute capacity at gigawatt-scale on an attractive timeline Venture Global, Inc. (NYSE: VG) today announced it has entered into power and grid frame agreements with GE Vernova and Baker Hughes Energy Services for up to 16 new, 720 MW power island units and associated power transformer equipment, supporting the continued expansion of its existing behind-the-meter, Island-Mode industrial power network that is not reliant on the grid. The a
Moncler Re/Icons: Cher, JENNIE and Grace Jones Re/Define What It Means to Be a Pioneer15.10.2026 12:00:00 CEST | Press release
Since its origins, Moncler has been at the forefront of the ascent, equipping the world’s most intrepid pioneers – those first to explore, so others can follow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015573482/en/ MONCLER RE/ICONS CHER That spirit lives on in the new Moncler Re/Icons collection, which takes iconic styles from the brand’s archives and reimagines them for a new generation, brought to life by three cultural pioneers who have forged their own extraordinary paths: Cher, JENNIE and Grace Jones. Each has spent a career making moves, moving mountains and reaching for higher peaks, refusing to follow the path already laid out before them. Pioneers in their own singular ways, they have blazed trails for others to follow and built enduring legacies that continue to shape what comes next. Inspired by archival photographs of alpine pioneer and early Moncler collaborator Lionel Terray, the campaign brings our p
AI Investment Is Surging, but Businesses Are Struggling to Prove the Value, HTEC Global Study Finds15.10.2026 10:42:00 CEST | Press release
Research among 1,500 C-suite executives finds 77% believe people and processes now constrain AI value more than technology HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015407055/en/ HTEC, a global product engineering and AI transformation company, today launches The HTEC AI Value Realization Report 2026, revealing a new challenge emerging as organizations move beyond AI experimentation: investment is accelerating faster than many companies’ ability to measure, govern and consistently realize its value. The independent study finds that 79% of organizations have increased AI investment over the past ye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom